The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics

AAPS Journal

Volumn 15, Issue 1, 2013, Pages 172-182

  Perez Ruixo, Juan Jose ^a   Ma, Peiming ^a   Chow, Andrew T ^a  

^a AMGEN INC   (United States)

Author keywords

immunogenicity; modeling and simulation; pharmacokinetics; therapeutic proteins

Indexed keywords

ADALIMUMAB; AMG 317; INFLIXIMAB; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ASTHMA; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; PHARMACODYNAMICS; POPULATION MODEL; REVIEW; SIMULATION;

ANTIBODIES, MONOCLONAL; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL;

EID: 84871955984     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9424-8     Document Type: Review

References (39)

1. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002;1:457-62. (Pubitemid 37361488)
2. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24:1720-40. (Pubitemid 35440946)
3. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20 Suppl 6:3-9.
4. Singh K. Impact of product-related factors ion immunogenicity of biotherapeutics. J Pharm Sci. 2011;100:354-87.
5. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-31. (Pubitemid 47300423)
6. Kokate CK, Jalalpure SS, Hurakadle PJ. Textbook of pharmaceutical biotechnology. New Delhi: Elsevier; 2011. p. 22-23.
7. Gell PGH, Coombs RRA, editors. Clinical aspects of immunology. 1st ed. Oxford: Blackwell; 1963.
8. Tabrizi MT, Tseng C-ML, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11:81-8. (Pubitemid 43227856)
9. Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev. 2008;14:191-202. (Pubitemid 351903454)
10. Gorovits B. Immunogenicity: prediction, detection and effective assay development. Bioanalysis. 2010;2:1539-45.
11. Putnam WS, Prabhu S, Zheng Y, Subramanyam M, Wang YMC. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol. 2010;28:509-16.
12. FDA. FDA guidance for industry: population pharmacokinetics. 1999. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM072137.pdf. Accessed 2 Nov 2012.
13. CHMP. CHMP guideline on reporting the result of population pharmacokinetic analyses. Doc. Ref. EMEA/CHMP/EWP/185990/06. 2007. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003067.pdf. Accessed 2 Nov 2012.
14. Richards SM. Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders. Clin Appl Immunol Rev. 2002;2:241-53. (Pubitemid 35439108)
15. Bonate PL, Sung C, Welch K, Richards S. Conditional modeling of antibody titers using a zero-inflated poisson random effects model: application to Fabrazyme. J Pharmacokinet Pharmacodyn. 2009;36:443-59.
16. Kianifard F, Gallo PP. Poisson regression analysis in clinical research. J Biopharm Stat. 1995;5:115-29.
17. Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OØ, Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44:774-81.
18. Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91:635-46.
19. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633-59.
20. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548-58.
21. Kakkar T, Sung C, Gibiansky L, Vu T, Narayanan A, Lin SL, et al. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm Res. 2011;28:2530-42.
22. Gibiansky L, Gibiansky E, Kakkar T, Ma P. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2008;35:573-91.
23. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507-32. (Pubitemid 34289541)
24. Xu ZH, Lee H, Vu T, Hu C, Yan H, Baker D, et al. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity. Int J Clin Pharmacol Ther. 2010;48:596-607.
25. Mahmood I, Green MD. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet. 2005;44:331-47. (Pubitemid 40663681)
26. Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008;30:523-9.
27. Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, Yeilding N, Davis HM, Zhou H. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49:162-75.
28. Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65:1211-28.
29. CHMP. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. Doc. Ref. EMEA/CHMP/BMWP/14327/2006. 2007. http://www.tga.gov.au/pdf/euguide/bmwp1432706en.pdf. Accessed 2 Nov 2012.
30. Weeraratne D, Chen A, Pennucci JJ, Wu CY, Zhang K, Wright J, et al. Incidence of anti-panitumumab antibodies is low and has no apparent impact on pharmacokinetic or safety profiles in clinical trials of panitumumab plus chemotherapy. BMC Clin Pharmacol. 2011;11:17.
31. Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007;110:980-8. (Pubitemid 47312862)
32. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-64. (Pubitemid 46797944)
33. Ma P, Yang BB, Wang YM, Peterson M, Narayanan A, Sutjandra L, et al. Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. J Clin Pharmacol. 2009;49:1142-56.
34. Olsson-Gisleskog P, Karlsson MO, Beal SL. Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn. 2002;29:473-505.
35. Cella M, Gorter de Vries F, Burger D, Danhof M, Della Pasqua O. A model-based approach to dose selection in early pediatric development. Clin Pharmacol Ther. 2010;87:294-302.
36. Perez-Ruixo JJ, Doshi S, Chow AT. Application of pharmacokinetic- pharmacodynamic modeling and simulation for erythropoietic stimulating agents. In: Kimko HHC, Peck CC, editors. Clinical trial simulations. Applications and trends. New York: Springer; 2010. p. 311-28.
37. Wang YM, Krzyzansky W, Doshi S, Xiao JJ, Pérez-Ruixo JJ, Chow AT. Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J. 2010;12:729-40.
38. Lecluse LL, Driessen RJ, Spuls PI, de Jong EM, Stapel SO, van Doorn MB, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010;146:127-32.
39. de Vries MK, Wolbink GJ, Stapel SO, de Groot ER, Dijkmans BA, Aarden LA, et al. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis. 2007;66:133-4. (Pubitemid 46044875)